Clerkenwell Hires Experienced Clinical Research Director
Clerkenwell is pleased to announce the appointment of Helen McAskill as its Clinical Research Director.
The new appointment adds significant healthcare and pharmaceutical sector experience to Clerkenwell, strengthening its position for offering clinical research support services and psychedelic-assisted therapies.
As Clinical Research Director, Helen will be responsible for the operational delivery and oversight of Clerkenwell’s research Centre of Excellence, programme management and clinical operations.
Helen has held leadership positions in clinical research for over 15 years with a special interest in mental health, including designing and developing governmental specialist services and policy. She has spent much of her career as a senior leader in clinical operations and site set up, with a focus on delivering efficient and effective complex trials, including the first Sativex trials in the UK for GW Pharma. She has extensive experience in strategic operations within research and healthcare environments as well as in technology and data.
“I am very happy to have joined the team at Clerkenwell Health in very exciting times. The team have designed an exceptional model, which aims to provide patients with therapeutic alternatives to support the management of mental health, and also gives drug developers the supportive expertise to study their products with a clear route to market,” said Helen McAskill.
“As a clinician and senior operator, I am passionate about ensuring mental health provision is enhanced with strong research programmes and products. Research and effective transformative therapies will go a significant way to support the rising incidence of mental health and treatment resistant conditions in our communities.”
Clerkenwell Health CEO, Tom McDonald commented, “Helen has been a fantastic addition to the team and her wealth of experience in the operational aspects of setting-up clinical research sites and studies will be invaluable as we support our clients through their phase I & II trials.”
Clerkenwell Health continues to build out their team and expertise needed to run a specialist drug development platform at scale, providing trials and support to psychedelic drug developers.